After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares.
With that, investors should recognize the revenue potential of VistaGen. With a market opportunity that is expected to be larger than 15 billion in 2026, VistaGen remains an interesting name. As of today, waiting for a buy the dip opportunity seems the correct trading strategy here.
Business
Incorporated in Nevada and headquartered in San Francisco, California,